WaveMan
WaveMan · Company
ONCO · Onconetix, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ONCO Onconetix (ONCO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001782107
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter

Onconetix insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Onconetix, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
HRT FINANCIAL LP
SELL
2026-04-22 SECtraded 2026-04-21
49,710
$34.3K
-94.0%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (3 buys, 2 sales), the last on Apr 20, 2026.
  • -89.3% median (-89.6% mean) 90-day return after 3 previous buys.
  • The trade is 147.7% of the 33,649 shares held after it.
  • No other insider sold within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP sold about $34.3K of ONCO on Apr 21, 2026; 5 funds added in the latest 13F quarter.
HRT FINANCIAL LP
SELL
2026-04-21 SECtraded 2026-04-20
94,462
$70.8K
-94.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on Apr 17, 2026.
  • -89.3% median (-89.6% mean) 90-day return after 3 previous buys.
  • The trade is 113.3% of the 83,359 shares held after it.
  • No other insider sold within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP sold about $70.8K of ONCO on Apr 20, 2026, the largest insider sale at the company on our record; 5 funds added in the latest 13F quarter.
HRT FINANCIAL LP
BUY
2026-04-21 SECtraded 2026-04-17
34,636
$25.3K
-94.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Apr 16, 2026.
  • -89.7% median (-89.7% mean) 90-day return after 2 previous buys.
  • The trade is 19.5% of the 177,821 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP bought about $25.3K of ONCO on Apr 17, 2026; 5 funds added in the latest 13F quarter.
HRT FINANCIAL LP
SELL
2026-04-21 SECtraded 2026-04-16
53,867
$39.3K
-94.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 15, 2026.
  • -89.7% median (-89.7% mean) 90-day return after 2 previous buys.
  • The trade is 37.6% of the 143,185 shares held after it.
  • No other insider sold within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP sold about $39.3K of ONCO on Apr 16, 2026, the largest insider sale at the company on our record; 5 funds added in the latest 13F quarter.
HRT FINANCIAL LP
BUY
2026-04-16 SECtraded 2026-04-15
92,554
$70.3K
-94.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 14, 2026.
  • The trade is 47.0% of the 197,052 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP bought about $70.3K of ONCO on Apr 15, 2026, the largest insider purchase at the company on our record; 5 funds added in the latest 13F quarter.
6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 1 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
-67.7% year over year
below 85% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
9.9% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
more than 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ONCO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.8%12M
-100%-62%-25%+13%2025-102025-122026-022026-042026-062026-082026-10 2026-04-20 · HRT FINANCIAL LP sold $70.8K2026-04-15 · HRT FINANCIAL LP bought $70.3K2026-04-14 · HRT FINANCIAL LP bought $57.2K2026-04-16 · HRT FINANCIAL LP sold $39.3K2026-04-21 · HRT FINANCIAL LP sold $34.3K2026-04-17 · HRT FINANCIAL LP bought $25.3K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ONCO: institutional holders (13F)

13F holdings, latest reported quarter
XTX Topco Ltd
13,548 sh
$15.3K
SBI Securities Co., Ltd.
252 sh
$285
Tower Research Capital LLC (TRC)
145 sh
$164
HOLLENCREST CAPITAL MANAGEMENT
100 sh
$113
HRT FINANCIAL LP
51,398 sh
$58

Congress trades in ONCO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ONCO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ONCO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$1.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ONCO financials

Revenue growth
-67.7%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$645.8K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$10.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-105.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-57.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-163.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-656.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$815.4K$2.5M$58.5Kn/a
Gross profit$632.9K$1.1M-$1.1Mn/a
Operating income-$17.9M-$56.5M-$36.0M-$13.5M
Net income-$14.0M-$58.7M-$37.4M-$13.4M
EPS (diluted)-16.56-1,823.39-87.45-1.10
Operating cash flow-$9.7M-$10.5M-$13.6M-$8.7M
Cashn/an/an/a$25.8M
Buybacksn/an/an/a$566.8K
SEC XBRL, fiscal years, as known on 2026-10-28

ONCO Stock Sonar score 4/7 axes

Find similar shapesCompare

ONCO ranks highest on risk and compliance (56th percentile) and profitability (29th), and lowest on institutional and government (5th), among Pharma & Biotech peers.

Profitability
29
Inputs
  • Return on equity-105.2% · 32 pct, sector of 545
  • Return on assets-57.4% · 40 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-163.8% · 14 pct, sector of 576
Growth
15
Inputs
  • Revenue growth, YoY-67.7% · 15 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
5
Inputs
  • Funds adding, latest quarter5 · 5 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
56
Inputs
  • Short interest, % of float+9.9% · 40 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.8% · 73 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies